Evidence map›Paper›PMID 20823136›Full record

ArticleHaematologica2010

Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms.

Philip A Beer, Christina A Ortmann, Frank Stegelmann, Paola Guglielmelli, John T Reilly, Thomas S Larsen, Hans C Hasselbalch, Alessandro M Vannucchi, Peter Möller, Konstanze Döhner and 1 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Unraveling the role ofHemaSphere · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 5 countries.

Philip A BeerCambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Hills Road, Cambridge, UK.
Christina A Ortmann
Frank Stegelmann
Paola Guglielmelli
John T Reilly
Thomas S Larsen
Hans C Hasselbalch
Alessandro M Vannucchi
Peter Möller
Konstanze Döhner
Anthony R Green
University Hospital Ulm · DEUniversity of Cambridge · GBOdense University Hospital · DKUniversity of Florence · ITRoyal Hallamshire Hospital · GB

Funding

Cancer Research UK 8961Medical Research Council
6 · The paper itself

Abstract

Somatic activating mutations in MPL, the thrombopoietin receptor, occur in the myeloproliferative neoplasms, although virtually nothing is known about their role in evolution to acute myeloid leukemia. In this study, the MPL T487A mutation, identified in de novo acute myeloid leukemia, was not detected in 172 patients with a myeloproliferative neoplasm. In patients with a prior MPL W515L-mutant myeloproliferative neoplasm, leukemic transformation was accompanied by MPL-mutant leukemic blasts, was seen in the absence of prior cytoreductive therapy and often involved loss of wild-type MPL by mitotic recombination. Moreover, clonal analysis of progenitor colonies at the time of leukemic transformation revealed the presence of multiple genetically distinct but phylogenetically-related clones bearing different TP53 mutations, implying a mutator-phenotype and indicating that leukemic transformation may be preceded by the parallel expansion of diverse hematopoietic clones.

Indexed as

MutationAcute DiseaseAmino Acid SubstitutionCell Transformation, NeoplasticCohort StudiesDioxygenasesDisease ProgressionDNA-Binding ProteinsHumansLeukemia, MyeloidModels, GeneticMyeloproliferative DisordersProto-Oncogene ProteinsReceptors, ThrombopoietinTumor Suppressor Protein p53DioxygenasesDNA-Binding ProteinsMPL protein, humanProto-Oncogene ProteinsReceptors, ThrombopoietinTET2 protein, humanTumor Suppressor Protein p53

Identifiers

PMID20823136
PMCPMC2995575
OpenAlexW2148504372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.